ProKidney Corp [PROK] stock is trading at $2.33, down -0.43%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PROK shares have gain 8.88% over the last week, with a monthly amount glided 7.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ProKidney Corp [NASDAQ: PROK] stock has seen the most recent analyst activity on December 16, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $12. Previously, BofA Securities downgraded its rating to Underperform on June 30, 2025, and kept the price target unchanged to $1. On September 30, 2024, JP Morgan initiated with a Neutral rating. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $6 on September 10, 2024. BofA Securities downgraded its rating to Neutral for this stock on January 02, 2024. In a note dated July 25, 2023, BTIG Research initiated a Buy rating and provided a target price of $16 on this stock.
ProKidney Corp [PROK] stock has fluctuated between $0.46 and $7.13 over the past year. Currently, Wall Street analysts expect the stock to reach $4.67 within the next 12 months. ProKidney Corp [NASDAQ: PROK] shares were valued at $2.33 at the most recent close of the market. An investor can expect a potential return of 100.43% based on the average PROK price forecast.
Analyzing the PROK fundamentals
Gross Profit Margin for this corporation currently stands at -0.88% with Operating Profit Margin at -230.12%, Pretax Profit Margin comes in at -209.06%, and Net Profit Margin reading is -95.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is 0.07 and Total Capital is -0.53. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, ProKidney Corp’s Current Ratio is 10.32. Also, the Quick Ratio is 10.32, while the Cash Ratio stands at 3.28. Considering the valuation of this stock, the price to sales ratio is 947.22.
Transactions by insiders
Recent insider trading involved Pereira Brian JG, Director, that happened on Nov 13 ’25 when 0.5 million shares were sold. Director, Pereira Brian JG completed a deal on Nov 12 ’25 to sell 0.26 million shares. Meanwhile, Director Brian Pereira bought 0.68 million shares on Nov 12 ’25.
